These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9859967)

  • 21. Participation in two phase II prophylactic HIV vaccine trials in the UK.
    Gray K; Legg K; Sharp A; Mackie N; Olarinde F; De Souza C; Weber J; Peters B
    Vaccine; 2008 Jun; 26(23):2919-24. PubMed ID: 18450339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.
    Andrasik MP; Sesay FA; Isaacs A; Oseso L; Allen M
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):488-496. PubMed ID: 32692107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa.
    Schmidt C; Jaoko W; Omosa-Manyonyi G; Kaleebu P; Mpendo J; Nanvubya A; Karita E; Bayingana R; Bekker LG; Chomba E; Kilembe W; Nchabeleng M; Nyombayire J; Stevens G; Chetty P; Lehrman J; Cox J; Allen S; Dally L; Smith C; Fast PE
    Hum Vaccin Immunother; 2014; 10(3):714-23. PubMed ID: 24374365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group.
    Belshe RB; Clements ML; Keefer MC; Graham BS; Corey L; Sposto R; Wescott S; Lawrence D
    Ann Intern Med; 1994 Oct; 121(8):584-9. PubMed ID: 8085690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
    Khurana S; Needham J; Mathieson B; Rodriguez-Chavez IR; Catanzaro AT; Bailer RT; Kim J; Polonis V; Cooper DA; Guerin J; Peterson ML; Gurwith M; Nguyen N; Graham BS; Golding H
    J Virol; 2006 Mar; 80(5):2092-9. PubMed ID: 16474117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults-Experience from Kenya.
    Nyasani DK; Mutua GN; Sajabi RM; Ng'ang'a JW; Gachie JN; Maina AM; Lusike LL; Anzala AO; Price MA; Manyonyi GO
    PLoS One; 2018; 13(11):e0206656. PubMed ID: 30388145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting hypothetical willingness to participate (WTP) in a future phase III HIV vaccine trial among high-risk adolescents.
    Giocos G; Kagee A; Swartz L
    AIDS Behav; 2008 Nov; 12(6):842-51. PubMed ID: 17668313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personal experiences following acquiring HIV infection while volunteering in Phase I/II HIV vaccine trials: A qualitative study from Tanzania.
    Tarimo EAM; Ambikile J; Munseri P; Bakari M
    PLoS One; 2022; 17(10):e0276404. PubMed ID: 36288332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual Behaviours and Practices before and after Phase I/II HIV Vaccine Trial: A Qualitative Study among Volunteers in Dar es Salaam Tanzania.
    Iseselo MK; Tarimo EAM; Sandstrom E; Kulane A
    Int J Environ Res Public Health; 2020 Oct; 17(19):. PubMed ID: 33019597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic.
    Barrington C; Moreno L; Kerrigan D
    AIDS Care; 2007 Aug; 19(7):871-7. PubMed ID: 17712690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya.
    Nyaoke BA; Mutua GN; Sajabi R; Nyasani D; Mureithi MW; Anzala OA
    PLoS One; 2017; 12(9):e0183788. PubMed ID: 28880880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contextualizing willingness to participate: recommendations for engagement, recruitment & enrolment of Kenyan MSM in future HIV prevention trials.
    Doshi M; Avery L; Kaddu RP; Gichuhi M; Gakii G; du Plessis E; Dutta S; Khan S; Kimani J; Lorway RR
    BMC Public Health; 2017 May; 17(1):469. PubMed ID: 28521748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demographic and AIDS-related characteristics of consenters to a population-based HIV-survey: results from a pilot study in Arusha, Tanzania.
    Ole-King'Ori N; Klepp KI; Kissila PE; Biswalo PM; Mnyika KS
    East Afr Med J; 1994 Aug; 71(8):483-9. PubMed ID: 7867536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania.
    Tarimo EAM; Ambikile J; Munseri P; Bakari M
    PLoS One; 2019; 14(11):e0224831. PubMed ID: 31703092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Being "False Positive": An "Inconvenience"? Debates and Questions Regarding the Notion of Vaccine-Induced Seropositivity (VISP) in the Recruitment of Healthy Volunteers for a Preventive Anti-HIV Vaccine Trial.
    Couderc M
    J Acquir Immune Defic Syndr; 2018 Oct; 79 Suppl 1():S20-S29. PubMed ID: 30222702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?
    Newman PA; Duan N; Rudy ET; Anton PA
    AIDS Patient Care STDS; 2004 Dec; 18(12):691-701. PubMed ID: 15659880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities.
    Strauss RP; Sengupta S; Kegeles S; McLellan E; Metzger D; Eyre S; Khanani F; Emrick CB; MacQueen KM
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):63-71. PubMed ID: 11176270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV vaccines in infants and children.
    Lambert JS
    Paediatr Drugs; 2005; 7(5):267-76. PubMed ID: 16220994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR.
    Schwartz DH; Laeyendecker OB; Arango-Jaramillo S; Castillo RC; Reynolds MJ
    Lancet; 1997 Jul; 350(9073):256-9. PubMed ID: 9242803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.